Loading stock data…
$24.84-0.23 (-0.92%)
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
Zymeworks Inc. in the Healthcare sector is trading at $24.77 with a market capitalization of $2.1B. Wall Street consensus targets $41.21 (14 analysts), implying a +66.4% move over the next 12 months. The stock is currently 21% below its 52-week high of $31.34, remaining 1.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.59M↑ | $2.41M↓ | $2.52M↓ | $27.61M↓ | $48.73M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.15M↑ | -$47.15M↓ | -$44.12M↓ | -$22.06M↓ | -$623,000 |
| Net Income | -$45.02M↓ | -$44.16M↓ | -$41.21M↓ | -$19.60M↓ | $2.32M |
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a s...